Skip to main content

AYTU BIOPHARMA, INC

For the period ended Feb 3, 2026. Filed Feb 3, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Feb 3, 2026 · Filed Feb 3, 2026

Use the contents to explore the available documents and sections.

AYTU$1.83+1.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · (in thousands, except share data)

(in thousands, except share data)

December 31,June 30,
20252025
ASSETS
Current assets:
Cash and cash equivalents$30,025$30,952
Accounts receivable, net30,92331,155
Inventories8,65611,434
Prepaid expenses and other current assets6,6375,638
Total current assets76,24179,179
Non-current assets:
Property and equipment, net484532
Operating lease right-of-use assets9591,061
Intangible assets, net43,57842,201
Other non-current assets7381,204
Total non-current assets45,75944,998
Total assets$122,000$124,177
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$14,259$10,601
Accrued liabilities40,15638,164
Revolving credit facility9,0759,063
Current portion of debt1,8571,857
Other current liabilities2163,379
Total current liabilities65,56363,064
Non-current liabilities:
Debt, net of current portion9,99810,895
Derivative warrant liabilities27,33726,334
Other non-current liabilities4,9014,918
Total non-current liabilities42,23642,147
Stockholders’ equity:
Preferred stock, par value $0.0001; 50,000,000 shares authorized; no shares issued or outstanding——
Common stock, par value $0.0001; 200,000,000 shares authorized; 10,733,208 and 8,976,913 shares issued and outstanding, respectively11
Additional paid-in capital356,354352,500
Accumulated deficit(342,154)(333,535)
Total stockholders’ equity14,20118,966
Total liabilities and stockholders’ equity$122,000$124,177
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.